Get the Stockscreener App
6.86
3.24%
-0.23
After Hours:
6.87
0.010
+0.15%
Galmed Pharmaceuticals Ltd stock is traded at $6.86, with a volume of 164.61K.
It is down -3.24% in the last 24 hours and up +102.96% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.
See More
Previous Close:
$7.09
Open:
$7.03
24h Volume:
164.61K
Relative Volume:
0.07
Market Cap:
$4.43M
Revenue:
-
Net Income/Loss:
$-6.91M
P/E Ratio:
-1.0254
EPS:
-6.69
Net Cash Flow:
$-6.14M
1W Performance:
-26.63%
1M Performance:
+102.96%
6M Performance:
+65.08%
1Y Performance:
-7.80%
1-Day Range:
$6.7588
$7.50
1-Week Range:
$6.6001
$10.00
52-Week Range:
$2.73
$23.80
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Feb-04-20 | Initiated | Craig Hallum | Buy |
| Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-02-19 | Initiated | Canaccord Genuity | Buy |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Aug-02-18 | Reiterated | Maxim Group | Buy |
| Jul-13-18 | Initiated | Stifel | Buy |
| Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
| Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
| Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Initiated | ROTH Capital | Buy |
| Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Reiterated | Maxim Group | Buy |
| Aug-01-16 | Reiterated | Maxim Group | Buy |
| Jul-06-16 | Resumed | ROTH Capital | Buy |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
| May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.25% - MSN
(GLMD) Long Term Investment Analysis - Stock Traders Daily
Galmed reports positive results for Aramchol in NASH study By Investing.com - Investing.com Australia
Galmed reports positive results for Aramchol in NASH study By Investing.com - Investing.com South Africa
Galmed reports positive results for Aramchol in NASH study - Investing.com India
Galmed reports positive results for Aramchol in NASH study - Investing.com
Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology - PR Newswire
Post-Trade Analysis: Galmed Pharmaceuticals Ltd (GLMD) Slides -13.90, Closing at 8.05 - The Dwinnex
Take off with Galmed Pharmaceuticals Ltd (GLMD): Get ready for trading - SETE News
Understanding GLMD stock ratios for better investment decisions - US Post News
GLMD’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Optimistic Market Report Drives Galmed Pharmaceuticals (GLMD) Stock Upward - Stocks Telegraph
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs - GlobeNewswire
Galmed expands drug development to cancer and heart diseases - Investing.com
Galmed surges on plans to expand into cancer and heart disease drug development - XM
Galmed Pharmaceuticals Stock Is Soaring Thursday: Here's Why - Benzinga
Market Insights: Galmed Pharmaceuticals Ltd (GLMD)’s Notable Drop of -54.30, Closing at 6.90 - The Dwinnex
Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases - StockTitan
B. Riley FBR Downgrades Galmed Pharmaceuticals Ltd (GLMD) to a Neutral from a Buy - Knox Daily
Galmed Pharmaceuticals Down 53%, But Still Well Above Monday Closing Price - MarketWatch
US Stocks Mixed; General Mills Posts Upbeat Earnings - Benzinga
A new trading data show Galmed Pharmaceuticals Ltd (GLMD) is showing positive returns. - SETE News
Why Intuitive Machines Shares Are Trading Higher By Around 41%; Here Are 20 Stocks Moving Premarket - Benzinga
Those who invested in Neuren Pharmaceuticals (ASX:NEU) three years ago are up 576% - Yahoo Finance
Galmed Pharmaceuticals Surges 400%: What's Behind the Explosion? - MarketBeat
Gold Edges Lower; US Homebuilder Sentiment Rises For September - Benzinga
Galmed Pharmaceuticals Surges After Regaining Nasdaq Compliance - MarketWatch
Galmed Pharmaceuticals Ltd’s Banking’s 100-Day Moving Average at 4.01: Will the Stock Break Through? - The InvestChronicle
Stock Market news: Galmed Pharmaceuticals soars 283%, Intel up 3.49%, while Tupperware plunges 57% - Business Upturn
Express Scripts sues FTC and demands drug pricing report retraction - Yahoo! Voices
With its newest mac and cheese, Stouffer's expands beyond the freezer aisle to supermarket shelves - Yahoo! Voices
Merit Medical touts positive six-month data from WAVE trial - Yahoo! Voices
Lunds & Byerlys digitizes refrigeration compliance management - Yahoo! Voices
Crude Oil Gains Over 1%; US Business Inventories Increase In July - Benzinga
Philip Morris to sell Vectura for $198 million after health shift criticism - Yahoo Finance
Why Shares of Gannett Are Soaring Today - Yahoo Finance
Galmed Pharma stock hits 52-week high at $10.51 - Investing.com
FanDuel Parent Buys Italian Gaming Operator Snai for $2.56 Billion - Yahoo! Voices
Sonoma Pharmaceuticals Receives New FDA 510(k) Clearance with Expanded Indications for Over-the-Counter Microcyn(R)-Based Solution - Yahoo Finance
Intel's Amazon chip deal lifts investor confidence in money-losing foundry unit - Yahoo! Voices
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Yahoo Finance
Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results - Yahoo Finance
What Is the Dividend Payout for Enterprise Products Partners? - Yahoo! Voices
Sapphire Mills partners with XLANCE Srl on sustainable stretch technology - Yahoo! Voices
Express Scripts sues FTC over drug pricing report, court documents show - Yahoo Finance
Woodside Energy discussing partnerships for Driftwood LNG project - Yahoo! Voices
Why Intel Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Benzinga
First Quantum launches voluntary retirement scheme for Cobre Panama staff - Yahoo! Voices
Retrieval-augmented generation enters boardroom discussions around GenAI – GlobalData - Yahoo! Voices
Galmed Pharmaceuticals Regains Nasdaq Compliance - TipRanks
Despite Being First Mover, BioMarin's Voxzogo For Dwarfism To Face Pressure From Ascendis' Candidate In Near Term - Yahoo Finance
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):